Prelude Capital Management’s Taysha Gene Therapies TSHA Stock Holding History
Bought
Maintained
Sold
Other funds holding TSHA
Prelude Capital Management's TSHA Position: Q3 2026 in Review
Prelude Capital Management sold out of Taysha Gene Therapies (TSHA) in Q3 2026, closing a stake of 98,346 shares — an estimated $670K sold.
Prelude Capital Management first reported a position in TSHA in Q3 2023 and held it in 5 quarters. The position peaked at $759K in Q3 2023. 205 funds tracked by Wall St. Rank hold TSHA as of Q3 2026.
- Prelude Capital Management reported no remaining Taysha Gene Therapies position as of Q3 2026 after selling out during the quarter.
- Prelude Capital Management sold 98,346 Taysha Gene Therapies shares in Q3 2026, an estimated $670K.
- Prelude Capital Management first reported a position in Taysha Gene Therapies in Q3 2023 and held it in 5 quarters.
- Prelude Capital Management's Taysha Gene Therapies position peaked at $759K in Q3 2023.
- 205 funds tracked by Wall St. Rank held Taysha Gene Therapies as of Q3 2026.
Based on Prelude Capital Management's 13F filing for Q3 2026, filed 16 Nov 2026.